Harbour Biomed prices IPO above mid point

Jonathan Breen

December 07, 2020 08:15 am

Healthcare medical biopharmaceutical investing stock chart background | Kurhan - stock.adobe.com

Harbour Biomed has pocketed HK$1.71bn ($220.8m) by pricing its IPO just above the mid point of the marketed range.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login

Topics

CITIC Securities Credit Suisse Equity IPOs Health and Biotech Equity China Merchants Bank Co China China International Capital Corp Hong Kong SAR Asia Greater China Haitong Securities Northeast Asia Guotai Junan Securities Co Asia Pacific SRI Bank of America Morgan Stanley Emerging Markets

JB

Jonathan Breen

Equities editor GlobalCapital Asia